New Alliance formed to address clinical trials in oncology | The Bulletin
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia | SpringerLink
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. - Abstract - Europe PMC
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib Versus FCR: A "Paradigm Shift" for Younger Patients With Treatment-Naïve CLL
Cancer and Leukemia Group B (CALGB)/Alliance 90203 trial (NCT00430183)... | Download Scientific Diagram
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia | Trials | Full Text
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
IVO vs IO Phase 3 Trial of the Impact of Adding Venetoclax to Ibrutinib and Obinutuzumab in CLL
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia -
SEQUOIA: zanubrutinib in CLL/SLL - Slideset Download - Hematology 2021 | CCO
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials - ScienceDirect
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
CONSORT diagram for Alliance/Cancer and Leukemia Group B 49907 trial.... | Download Scientific Diagram
Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy
Managing CLL With BTK Inhibitors - ppt download
Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
Diagnostics | Free Full-Text | The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment
![PDF] Initial treatment of CLL: integrating biology and functional status. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7b412b923e9a2dd4366134630d23613c24240fc9/19-Table2-1.png "PDF] Initial treatment of CLL: integrating biology and functional status. | Semantic Scholar")
PDF] Initial treatment of CLL: integrating biology and functional status. | Semantic Scholar
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Current Perspectives on Therapy for Chronic Lymphocytic Leukemia | American Society of Clinical Oncology Educational Book
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
